VXRT - Vaxart Inc Stock Price, Fair Value and News

$0.77-0.02 (-2.53%)

Delayed as of 23 Oct 2024, 03:04 pm ET

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

VXRT Price Action

Last 30 days

-4.8%

Last 90 days

17.9%

Trailing 12 Months

19.7%

VXRT RSI Chart

VXRT Valuation

Market Cap

179.7M

Price/Earnings (Trailing)

-2.37

Price/Sales (Trailing)

12.9

EV/EBITDA

-2.05

Price/Free Cashflow

-2.88

VXRT Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

VXRT Fundamentals

VXRT Revenue

Revenue (TTM)

13.9M

Rev. Growth (Yr)

371.35%

Rev. Growth (Qtr)

193.49%

VXRT Earnings

Earnings (TTM)

-75.7M

Earnings Growth (Yr)

26.98%

Earnings Growth (Qtr)

32.56%

VXRT Profitability

Operating Margin

-216.63%

EBT Margin

-541.20%

Return on Equity

-94.56%

Return on Assets

-66.51%

Free Cashflow Yield

-34.74%

VXRT Investor Care

Shares Dilution (1Y)

49.66%

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	8.9M	13.9M	0	0
2023	697.0K	2.1M	4.2M	7.4M
2022	471.0K	359.0K	159.0K	107.0K
2021	1.6M	1.2M	1.2M	892.0K
2020	7.4M	7.8M	7.6M	4.0M
2019	8.1M	7.5M	7.7M	9.9M
2018	5.0M	3.8M	3.2M	4.2M
2017	5.3M	3.2M	6.6M	5.8M
2016	0	11.5M	9.4M	7.4M
2015	23.5M	8.4M	13.6M	0
2014	69.5M	68.7M	53.6M	38.5M
2013	24.9M	33.6M	44.4M	52.5M
2012	14.0M	10.9M	11.2M	19.5M
2011	30.4M	29.3M	18.1M	16.1M
2010	0	18.7M	26.8M	35.0M
2009	0	0	0	10.5M

Get all data in R, Python etc through our Historical Stock Data APIs

About Vaxart Inc

Vaxart, Inc., a clinical-stage biotechnology company, engages in the discovery and development of oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, an oral tablet vaccine, which is in a Phase II clinical trial with bivalent oral tablet vaccine for the GI.1 and GII.4 norovirus strains; seasonal influenza vaccine, which is in Phase II clinical trial for the treatment of H1 influenza infection; respiratory syncytial virus vaccine, an oral vaccine platform, which is in preclinical stage; coronavirus vaccine, which is in Phase II clinical trial for the treatment of SARS-CoV-2 infection; human papillomavirus therapeutic vaccine that targets HPV 16 and HPV 18 for cervical cancers and precancerous cervical dysplasia. The company has license agreement with Altesa Biosciences, Inc. to develop and commercialize Vapendavir, a capsid-binding broad spectrum antiviral. Vaxart, Inc. is headquartered in South San Francisco, California.

CEO	Mr. Cezar Andrei Floroiu M.B.A.
WEBSITE	https://vaxart.com
SECTOR	Healthcare
INDUSTRY	Biotechnology
EMPLOYEES	164

Vaxart Inc Frequently Asked Questions

What is the ticker symbol for Vaxart Inc? What does VXRT stand for in stocks?

VXRT is the stock ticker symbol of Vaxart Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Vaxart Inc (VXRT)?

As of Tue Oct 22 2024, market cap of Vaxart Inc is 179.68 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of VXRT stock?

You can check VXRT's fair value in chart for subscribers.

Is Vaxart Inc a good stock to buy?

The fair value guage provides a quick view whether VXRT is over valued or under valued. Whether Vaxart Inc is cheap or expensive depends on the assumptions which impact Vaxart Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for VXRT.

What is Vaxart Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Tue Oct 22 2024, VXRT's PE ratio (Price to Earnings) is -2.37 and Price to Sales (PS) ratio is 12.9. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. VXRT PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Vaxart Inc's stock?

In the past 10 years, Vaxart Inc has provided -0.297 (multiply by 100 for percentage) rate of return.